- Home
- HL vs NBIX Comparison
HL vs NBIX Comparison
Compare HL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | NBIX |
|---|---|---|
| Founded | 1891 | 1992 |
| Country | United States | United States |
| Employees | N/A | 1800 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.9B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | HL | NBIX |
|---|---|---|
| Price | $23.21 | $138.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 21 |
| Target Price | $20.71 | ★ $176.24 |
| AVG Volume (30 Days) | ★ 31.1M | 1.0M |
| Earning Date | 02-17-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.06% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | 0.31 | ★ 4.19 |
| Revenue | $1,224,563,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $45.71 | $23.25 |
| Revenue Next Year | $20.37 | $19.46 |
| P/E Ratio | $77.33 | ★ $33.29 |
| Revenue Growth | ★ 45.62 | 19.61 |
| 52 Week Low | $4.46 | $84.23 |
| 52 Week High | $34.17 | $160.18 |
Technical Indicators
Market Signals| Indicator | HL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 49.87 |
| Support Level | $20.90 | $136.46 |
| Resistance Level | $24.12 | $142.15 |
| Average True Range (ATR) | 2.15 | 3.60 |
| MACD | -0.72 | 0.80 |
| Stochastic Oscillator | 17.14 | 55.16 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.